Melatonin (Synonyms: N-Acetyl-5-methoxytryptamine)

Name: Melatonin
Brand: MedChemExpress
SKU: HY-B0075
Rating: 5.0 (90 reviews)

Cat. No.: HY-B0075 Purity: 99.93%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Melatonin is a hormone made by the pineal gland that can activates melatonin receptor. Melatonin plays a role in sleep and possesses important antioxidative and anti-inflammatory properties. Melatonin is a novel selective ATF-6 inhibitor and induces human hepatoma cell apoptosis through COX-2 downregulation. Melatonin attenuates palmitic acid-induced (HY-N0830) mouse granulosa cells apoptosis via endoplasmic reticulum stress.

For research use only. We do not sell to patients.

Melatonin Chemical Structure

CAS No. : 73-31-4

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 33	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 33	In-stock	Estimated Time of Arrival: December 31
Solid
500 mg	USD 30	In-stock	Estimated Time of Arrival: December 31
1 g	USD 40	In-stock	Estimated Time of Arrival: December 31
5 g	USD 80	In-stock	Estimated Time of Arrival: December 31
10 g		Get quote
50 g		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 90 publication(s) in Google Scholar

Other Forms of Melatonin:

Melatonin-d₄ Get quote
Melatonin-d₃ Get quote
Melatonin-d₇ Get quote

88 Publications Citing Use of MCE Melatonin

: Melatonin purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2018 Oct;22(10):5132-5144. [Abstract]; Melatonin regulation of mitophagy activity in the diabetic myocardium, Protein expression with representative gel blots of LC3 I/II, GAPDH (loading control).

: Melatonin purchased from MedChemExpress. Usage Cited in: Molecules. 2018 Mar 16;23(3). pii: E675. [Abstract]; Representative image of immunobloting of UCP2 in the cultured AC16 cells under various treatments.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Melatonin Receptor Isoform Specific Products:

View All Isoforms

MT1 MT2

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

Melatonin is a hormone made by the pineal gland that can activates melatonin receptor. Melatonin plays a role in sleep and possesses important antioxidative and anti-inflammatory properties^[1]^[2]^[3]. Melatonin is a novel selective ATF-6 inhibitor and induces human hepatoma cell apoptosis through COX-2 downregulation^[4]. Melatonin attenuates palmitic acid-induced (HY-N0830) mouse granulosa cells apoptosis via endoplasmic reticulum stress^[5].

IC₅₀ & Target

Microbial Metabolite

Human Endogenous Metabolite

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	> 30 μM Compound: Melatonin	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 33248852]
AGS	IC₅₀	> 30 μM Compound: Melatonin	Antiproliferative activity against human AGS cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against human AGS cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 33248852]
BT-549	IC₅₀	30 mM Compound: Melatonin	Antiproliferative activity against human BT549 cells after 24 hrs by MTT assay Antiproliferative activity against human BT549 cells after 24 hrs by MTT assay	[PMID: 29144746]
C6	IC₅₀	> 40 μM Compound: Melatonin	Antiproliferative activity against rat C6 cells assessed as growth inhibition incubated for 72 hrs by CCK-8 assay Antiproliferative activity against rat C6 cells assessed as growth inhibition incubated for 72 hrs by CCK-8 assay	[PMID: 34091208]
CHO	EC₅₀	0.026 nM Compound: melatonin	Agonist activity at human MT1 receptor expressed in CHO cells assessed as decrease in forskolin-stimulated cAMP release after 30 mins by multilabel plate reader Agonist activity at human MT1 receptor expressed in CHO cells assessed as decrease in forskolin-stimulated cAMP release after 30 mins by multilabel plate reader	[PMID: 21568291]
CHO	EC₅₀	0.069 nM Compound: melatonin	Agonist activity at human melatonin receptor-2 transfected in CHO cell membranes after 1 hr by GTPgammaS binding assay Agonist activity at human melatonin receptor-2 transfected in CHO cell membranes after 1 hr by GTPgammaS binding assay	[PMID: 26023814]
CHO	EC₅₀	0.098 nM Compound: melatonin	Agonist activity at human melatonin receptor-1 transfected in CHO cell membranes after 1 hr by GTPgammaS binding assay Agonist activity at human melatonin receptor-1 transfected in CHO cell membranes after 1 hr by GTPgammaS binding assay	[PMID: 26023814]
CHO	EC₅₀	0.4 nM Compound: MLT	Intrinsic activity at human melatonin MT2 receptor expressed in CHO cells assessed as [35S]GTPgammaS binding after 1 hr Intrinsic activity at human melatonin MT2 receptor expressed in CHO cells assessed as [35S]GTPgammaS binding after 1 hr	[PMID: 24417958]
CHO	EC₅₀	0.49 nM Compound: 1	Agonist potency determined by [35S]GTP gamma-S binding assay using CHO cell lines for Melatonin receptor type 1B Agonist potency determined by [35S]GTP gamma-S binding assay using CHO cell lines for Melatonin receptor type 1B	[PMID: 12646022]
CHO	IC₅₀	1.1 x 10^-10 M Compound: Melatonin	Displacement of [125I]2-iodomelatonin from human recombinant MT1 receptor expressed in CHO cells measured after 60 mins by scintillation counting method Displacement of [125I]2-iodomelatonin from human recombinant MT1 receptor expressed in CHO cells measured after 60 mins by scintillation counting method	[PMID: 27876250]
CHO	EC₅₀	1.5 nM Compound: Melatonin	Agonist activity at human MT1 receptor expressed in CHO cells by [35S]GTPgamma binding assay Agonist activity at human MT1 receptor expressed in CHO cells by [35S]GTPgamma binding assay	[PMID: 21420861]
CHO	EC₅₀	1.7 nM Compound: MLT	Intrinsic activity at human melatonin MT1 receptor expressed in CHO cells assessed as [35S]GTPgammaS binding after 1 hr Intrinsic activity at human melatonin MT1 receptor expressed in CHO cells assessed as [35S]GTPgammaS binding after 1 hr	[PMID: 24417958]
CHO	EC₅₀	2.2 nM Compound: MLT	Agonist activity at human MT1 receptor expressed in CHO cells by [35S]GTPgamma binding assay Agonist activity at human MT1 receptor expressed in CHO cells by [35S]GTPgamma binding assay	[PMID: 20444610]
CHO	EC₅₀	2.24 nM Compound: 1	Agonist potency determined by [35S]GTP gamma-S binding assay using CHO cell lines for Melatonin receptor type 1A Agonist potency determined by [35S]GTP gamma-S binding assay using CHO cell lines for Melatonin receptor type 1A	[PMID: 12646022]
CHO-K1	IC₅₀	0.21 nM Compound: melatonin	Displacement of [125I]2-iodomelatonin from human recombinant melatonin receptor 1 expressed in CHOK1 cells after 3 hrs Displacement of [125I]2-iodomelatonin from human recombinant melatonin receptor 1 expressed in CHOK1 cells after 3 hrs	[PMID: 23403082]
HCT-116	IC₅₀	> 30 μM Compound: Melatonin	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 33248852]
HEK293	EC₅₀	1 nM Compound: Melatonin	Agonist activity at MT1 receptor (unknown origin) expressed in HEK293 cells by Fluo-8 dye-based calcium assay Agonist activity at MT1 receptor (unknown origin) expressed in HEK293 cells by Fluo-8 dye-based calcium assay	[PMID: 31204226]
HEK293	EC₅₀	25 nM Compound: Melatonin	Agonist activity at MT2 receptor (unknown origin) expressed in HEK293 cells by Fluo-8 dye-based calcium assay Agonist activity at MT2 receptor (unknown origin) expressed in HEK293 cells by Fluo-8 dye-based calcium assay	[PMID: 31204226]
HepG2	IC₅₀	> 30 μM Compound: Melatonin	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 33248852]
HepG2	IC₅₀	271 μM Compound: 1, MLT	Antioxidant activity in human HepG2 cells assessed as reduction in H2O2-induced oxidation by DCFH-DA assay Antioxidant activity in human HepG2 cells assessed as reduction in H2O2-induced oxidation by DCFH-DA assay	[PMID: 23332368]
HGC-27	IC₅₀	> 30 μM Compound: Melatonin	Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 33248852]
MCF7	IC₅₀	> 30 μM Compound: Melatonin	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 33248852]
MCF7	IC₅₀	18 mM Compound: Melatonin	Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 29144746]
MDA-MB-231	IC₅₀	0.9 μM Compound: Melatonin	Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 29144746]
MGC-803	IC₅₀	> 30 μM Compound: Melatonin	Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 33248852]
PC-12	IC₅₀	> 100 μM Compound: MLT	Neuroprotective activity against amyloid beta (25 to 35 amino acid residues) induced damage in rat PC12 cells assessed as cell viability preincubated for 3 hrs followed by addition of amyloid beta (25 to 35 amino acid residues) for 24 hrs by MTT assay Neuroprotective activity against amyloid beta (25 to 35 amino acid residues) induced damage in rat PC12 cells assessed as cell viability preincubated for 3 hrs followed by addition of amyloid beta (25 to 35 amino acid residues) for 24 hrs by MTT assay	[PMID: 26970662]
SGC-7901	IC₅₀	> 30 μM Compound: Melatonin	Antiproliferative activity against human SGC-7901 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against human SGC-7901 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 33248852]
SH-SY5Y	EC₅₀	> 1 μM Compound: Melatonin	Neuroprotective activity against t-BuOOH-induced oxidative stress in human SH-SY5Y cells assessed as inhibition ROS accumulation pre-incubated for 24 hrs before t-BuOOH challnge for 30 mins by DCFH-DA probe based fluorescence assay Neuroprotective activity against t-BuOOH-induced oxidative stress in human SH-SY5Y cells assessed as inhibition ROS accumulation pre-incubated for 24 hrs before t-BuOOH challnge for 30 mins by DCFH-DA probe based fluorescence assay	[PMID: 29420891]
U-251	IC₅₀	> 40 μM Compound: Melatonin	Antiproliferative activity against human U-251 cells assessed as growth inhibition incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human U-251 cells assessed as growth inhibition incubated for 72 hrs by CCK-8 assay	[PMID: 34091208]
U-87MG ATCC	IC₅₀	> 40 μM Compound: Melatonin	Antiproliferative activity against human U-87 MG cells assessed as growth inhibition incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human U-87 MG cells assessed as growth inhibition incubated for 72 hrs by CCK-8 assay	[PMID: 34091208]

In Vivo

Melatonin increases the levels of activated PTEN, RSK-1, mTOR and AMPKα kinases, mildly inhibits ERK-1/2 phosphorylation and Bad phosphorylation, significantly inhibits phosphorylations of S6 Ribosomal Protein, 4E-BP1, GSK-3α and GSK-3β, and slightly increases PRAS40 phosphorylation in animals^[1]. Melatonin ameliorates the neurotoxiciy and astrocyte activation induced by Aβ_1-42 in the cerebral cortex. Melatonin also blocks the reduction in Reelin and Dab1 expression induced by Aβ_1-42^[2]. Melatonin treatment and lack of NLRP3^-/- share similar inhibition of NF-κB and NLRP3 signaling pathway in mice. Melatonin treatment and lack of NLRP3^-/- share some patterns of clock genes expression, and improve cardiomyocytes morphology in mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

232.28

Formula

C₁₃H₁₆N₂O₂

CAS No.

73-31-4

Appearance

Solid

Color

White to light yellow

SMILES

CC(NCCC1=CNC2=C1C=C(OC)C=C2)=O

Structure Classification

Others

Initial Source

Microorganisms

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (430.51 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 12.5 mg/mL (53.81 mM; Need ultrasonic)

H₂O : 1.1 mg/mL (4.74 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.3051 mL	21.5257 mL	43.0515 mL
5 mM	0.8610 mL	4.3051 mL	8.6103 mL
10 mM	0.4305 mL	2.1526 mL	4.3051 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.76 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (10.76 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (10.76 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Protocol 4

Add each solvent one by one: 2% DMSO 40% PEG300 5% Tween-80 53% Saline
Solubility: ≥ 2.5 mg/mL (10.76 mM); Clear solution
Protocol 5

Add each solvent one by one: 2% DMSO 98% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (10.76 mM); Clear solution
Protocol 6

Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (5.38 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 7

Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 1.25 mg/mL (5.38 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (12.5 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 40% PEG300 60% Saline
Solubility: 15 mg/mL (64.58 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.93%

Select Batch:

Data Sheet (280 KB) SDS (393 KB)

COA (249 KB) HNMR (268 KB) LCMS (94 KB) Elemental Analysis Report (107 KB)

Handling Instructions (2659 KB)

References

[1]. Kilic U, et al. Particular phosphorylation of PI3K/Akt on Thr308 via PDK-1 and PTEN mediates melatonin's neuroprotective activity after focal cerebral ischemia in mice. Redox Biol. 2017 Apr 5;12:657-665 [Content Brief]

[2]. Hu C, et al. Neuroprotective effect of melatonin on soluble Aβ1-42-induced cortical neurodegeneration via Reelin-Dab1 signaling pathway. Neurol Res. 2017 Apr 7:1-1 [Content Brief]

[3]. Rahim I, et al. Melatonin administration to wild-type mice and non-treated NLRP3 mutant mice share similar inhibition of the inflammatory response during sepsis. J Pineal Res. 2017 Mar 31 [Content Brief]

[4]. Bu LJ, et al. Melatonin, a novel selective ATF-6 inhibitor, induces human hepatoma cell apoptosis through COX-2 downregulation. World J Gastroenterol. 2017 Feb 14;23(6):986-998. [Content Brief]

[5]. Zhi Chen, et al. Melatonin attenuates palmitic acid-induced mouse granulosa cells apoptosis via endoplasmic reticulum stress. J Ovarian Res. 2019 May 10;12(1):43. [Content Brief]

Animal Administration
^[1]

A total of two sets of adult male C57BL/6j mice weighing 21-26 g are randomly assigned to one of four groups and treated with intraperitoneal (i.p.) delivery of (i) vehicle (50 μL isotonic saline/5% ethanol), (ii) melatonin (4 mg/kg, dissolved in 0.9% isotonic saline/5% ethanol), (iii) Wortmannin, and (iv) melatonin/Wortmannin immediately after reperfusion. In the first set, mice are exposed to 30 min of focal cerebral ischemia (FCI) and 72 h reperfusion for the evaluation of disseminate ischemic injury in the striatum, and signaling pathway analysis (n=7 per group). The second group of mice is exposed to 90 min of FCI and 24 h reperfusion for the analysis of infarct development, brain swelling and IgG extravasation (n=7 per group).

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

[1]. Kilic U, et al. Particular phosphorylation of PI3K/Akt on Thr308 via PDK-1 and PTEN mediates melatonin's neuroprotective activity after focal cerebral ischemia in mice. Redox Biol. 2017 Apr 5;12:657-665 [Content Brief]

[2]. Hu C, et al. Neuroprotective effect of melatonin on soluble Aβ1-42-induced cortical neurodegeneration via Reelin-Dab1 signaling pathway. Neurol Res. 2017 Apr 7:1-1 [Content Brief]

[3]. Rahim I, et al. Melatonin administration to wild-type mice and non-treated NLRP3 mutant mice share similar inhibition of the inflammatory response during sepsis. J Pineal Res. 2017 Mar 31 [Content Brief]

[4]. Bu LJ, et al. Melatonin, a novel selective ATF-6 inhibitor, induces human hepatoma cell apoptosis through COX-2 downregulation. World J Gastroenterol. 2017 Feb 14;23(6):986-998. [Content Brief]

[5]. Zhi Chen, et al. Melatonin attenuates palmitic acid-induced mouse granulosa cells apoptosis via endoplasmic reticulum stress. J Ovarian Res. 2019 May 10;12(1):43. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O / Ethanol / DMSO	1 mM	4.3051 mL	21.5257 mL	43.0515 mL	107.6287 mL
Ethanol / DMSO	5 mM	0.8610 mL	4.3051 mL	8.6103 mL	21.5257 mL
	10 mM	0.4305 mL	2.1526 mL	4.3051 mL	10.7629 mL
	15 mM	0.2870 mL	1.4350 mL	2.8701 mL	7.1752 mL
	20 mM	0.2153 mL	1.0763 mL	2.1526 mL	5.3814 mL
	25 mM	0.1722 mL	0.8610 mL	1.7221 mL	4.3051 mL
	30 mM	0.1435 mL	0.7175 mL	1.4350 mL	3.5876 mL
	40 mM	0.1076 mL	0.5381 mL	1.0763 mL	2.6907 mL
	50 mM	0.0861 mL	0.4305 mL	0.8610 mL	2.1526 mL
DMSO	60 mM	0.0718 mL	0.3588 mL	0.7175 mL	1.7938 mL
	80 mM	0.0538 mL	0.2691 mL	0.5381 mL	1.3454 mL
	100 mM	0.0431 mL	0.2153 mL	0.4305 mL	1.0763 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Melatonin Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Melatonin73-31-4N-Acetyl-5-methoxytryptamineMelatonin ReceptorAutophagyMitophagyEndogenous MetaboliteApoptosisMitochondrial AutophagyInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Melatonin (Synonyms: N-Acetyl-5-methoxytryptamine)

Customer Review

Other Forms of Melatonin:

Melatonin Related Antibodies

88 Publications Citing Use of MCE Melatonin

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Melatonin Receptor Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Melatonin Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report